{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:13:19Z","timestamp":1791238399418,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2004,5]]},"DOI":"10.1124\/jpet.103.060806","type":"journal-article","created":{"date-parts":[[2004,4,22]],"date-time":"2004-04-22T00:29:43Z","timestamp":1082593783000},"page":"845-852","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["The Fenfluramine Metabolite (+)-Norfenfluramine Is Vasoactive"],"prefix":"10.1016","volume":"309","author":[{"given":"Wei","family":"Ni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa W.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keshari","family":"Thakali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory D.","family":"Fink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie W.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.103.060806_bib1","doi-asserted-by":"crossref","unstructured":"Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, Higenbottam T, Oakley C, Wouters E, Aubier M, et al. (1996) Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 355: 609-616.","DOI":"10.1056\/NEJM199608293350901"},{"key":"10.1124\/jpet.103.060806_bib2","doi-asserted-by":"crossref","unstructured":"Barnes NM and Sharp T (1999) A review of central 5-HT receptors and their function. Neuropharmacology 38: 1083-1152.","DOI":"10.1016\/S0028-3908(99)00010-6"},{"key":"10.1124\/jpet.103.060806_bib3","doi-asserted-by":"crossref","unstructured":"Chiang BN, Perlman LV, and Epstein FH (1969) Overweight and hypertension. Circulation 39: 403-421.","DOI":"10.1161\/01.CIR.39.3.403"},{"key":"10.1124\/jpet.103.060806_bib4","doi-asserted-by":"crossref","unstructured":"Cohen ML, Schenck KW, and Kurz KD (1988) 5-HT2 receptor antagonists: \u03b11 vs 5-HT2-receptor blocking properties in blood vessels. J Cardiovasc Pharmacol 11 (Suppl 1): S25-S29.","DOI":"10.1097\/00005344-198811001-00007"},{"key":"10.1124\/jpet.103.060806_bib5","unstructured":"Cohen ML, Schenck KW, Mabry TE, Nelson DL, and Audia JE (1996) LY272015, a potent, selective and orally active 5-HT2B receptor antagonist. J Ser Res 3: 131-144."},{"key":"10.1124\/jpet.103.060806_bib6","doi-asserted-by":"crossref","unstructured":"Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, and Schaff HV (1997) Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337: 581-588.","DOI":"10.1056\/NEJM199708283370901"},{"key":"10.1124\/jpet.103.060806_bib7","doi-asserted-by":"crossref","unstructured":"Desta B, Steed S, Ravel D, Laudignon N, Vanhoutte PM, and Boulanger CM (1998) Acute and chronic effects of dexfenfluramine on the porcine pulmonary artery. Gen Pharmacol 30: 403-410.","DOI":"10.1016\/S0306-3623(97)00278-4"},{"key":"10.1124\/jpet.103.060806_bib8","doi-asserted-by":"crossref","unstructured":"Flechtner-Mors M, Ditschuneit HH, Yip I, and Adler G (1988) Blood pressure and plasma norepinephrine responses to dexfenfluramine in obese postmenopausal women. Am J Clin Nutr 67: 611-615.","DOI":"10.1093\/ajcn\/67.4.611"},{"key":"10.1124\/jpet.103.060806_bib9","doi-asserted-by":"crossref","unstructured":"Foguet M, Hoyer D, Pardo LA, Parekh A, Kluxen FW, Kalkman HO, Stuhmer W, and Lubbert H (1992) Cloning and functional characterization of the rat stomach fundus serotonin receptor. EMBO (Eur Mol Biol Organ) J 11: 3481-3487.","DOI":"10.1002\/j.1460-2075.1992.tb05427.x"},{"key":"10.1124\/jpet.103.060806_bib10","doi-asserted-by":"crossref","unstructured":"Garattini S (1995) Biological actions of drugs affecting serotonin and eating. Obes Res 3 (Suppl 4): 463S-470S.","DOI":"10.1002\/j.1550-8528.1995.tb00213.x"},{"key":"10.1124\/jpet.103.060806_bib11","doi-asserted-by":"crossref","unstructured":"Jones SB, Smith JM, Jones AW, and Bylund DB (1987) Alpha-1 adrenergic receptor binding in aortas from rat and dog: comparison of [3H]prazosin and beta-iodo-[125I]-4-hydroxyphenyl-ethyl-aminomethyl-tetralone. J Pharmacol Exp Ther 241: 875-881.","DOI":"10.1016\/S0022-5347(25)00196-X"},{"key":"10.1124\/jpet.103.060806_bib12","doi-asserted-by":"crossref","unstructured":"Korstanje C, Sprenkels R, Doods HN, Hugtenburg JG, Boddeke E, Batink HD, Thoolen MJ, and Van Zwieten PA (1986) Characterization of flufylline, fluprofylline, ritanserin, butanserin and R 56413 with respect to in-vivo alpha 1-,alpha2-and 5-HT2-receptor antagonism and in-vitro affinity for alpha1-,alpha2- and 5-HT2-receptors: comparison with ketanserin. J Pharm Pharmacol 38: 374-379.","DOI":"10.1111\/j.2042-7158.1986.tb04590.x"},{"key":"10.1124\/jpet.103.060806_bib13","doi-asserted-by":"crossref","unstructured":"Kursar JD, Nelson DL, Wainscott DB, Cohen ML, and Baez M (1992) Molecular cloning, functional expression and pharmacological characterization of a novel serotonin receptor (5-hydroxytryptamine2F) from rat stomach fundus. Mol Pharmacol 42: 549-557.","DOI":"10.1016\/S0026-895X(25)08969-2"},{"key":"10.1124\/jpet.103.060806_bib14","doi-asserted-by":"crossref","unstructured":"Leysen JE, Niemegeers CJ, Van Nueten JM, and Laduron PM (1982) [3H]Ketanserin (R 41 468), a selective 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution and functional role. Mol Pharmacol 21: 301-314.","DOI":"10.1016\/S0026-895X(25)14623-3"},{"key":"10.1124\/jpet.103.060806_bib15","unstructured":"Mabadeje AF (1974) Proceedings: fenfluramine-induced hypertension. West Afr J Pharmacol Drug Res 2: 54."},{"key":"10.1124\/jpet.103.060806_bib16","doi-asserted-by":"crossref","unstructured":"Martin GR (1994) Vascular receptors for 5-hydroxytryptamine: distribution, function and classification. Pharmacol Ther 62: 283-324.","DOI":"10.1016\/0163-7258(94)90048-5"},{"key":"10.1124\/jpet.103.060806_bib17","doi-asserted-by":"crossref","unstructured":"McCafferty DM, Wallace JL, and Sharkey KA (1997) Effects of chemical sympathectomy and sensory nerve ablation on experimental colitis in the rat. Am J Physiol 272: G272-G280.","DOI":"10.1152\/ajpgi.1997.272.2.G272"},{"key":"10.1124\/jpet.103.060806_bib18","doi-asserted-by":"crossref","unstructured":"Michelakis ED, Weir EK, Nelson DP, Reeve HL, Tolarova S, and Archer SL (1999) Dexfenfluramine elevates systemic blood pressure by inhibiting potassium currents in vascular smooth muscle cells. J Pharmacol Exp Ther 291: 1143-1149.","DOI":"10.1016\/S0022-3565(24)35220-6"},{"key":"10.1124\/jpet.103.060806_bib19","doi-asserted-by":"crossref","unstructured":"Montani J-P, Antic V, Yang Z, and Dulloo Abdul (2002) Pathways from obesity to hypertension: from the perspective of a vicious triangle. Int J Obesity 26 (Suppl 2): S28-S38.","DOI":"10.1038\/sj.ijo.0802125"},{"key":"10.1124\/jpet.103.060806_bib20","doi-asserted-by":"crossref","unstructured":"Naselsky DP, Ashton D, Ruffolo RR, and Hieble JP (2001) Rabbit alpha2-adrenoceptors: both platelets and adipocytes have alpha2A-pharmacology. J Pharmacol Exp Ther 298: 219-225.","DOI":"10.1016\/S0022-3565(24)29371-X"},{"key":"10.1124\/jpet.103.060806_bib21","unstructured":"Oates HF (1979) Relationship between the hypotensive and alpha-adrenoceptor blocking actions of prazosin. Arch Int Pharmacodyn Ther 237: 282-287."},{"key":"10.1124\/jpet.103.060806_bib22","doi-asserted-by":"crossref","unstructured":"Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, and Roth BL (2000) Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102: 2836-2841.","DOI":"10.1161\/01.CIR.102.23.2836"},{"key":"10.1124\/jpet.103.060806_bib23","doi-asserted-by":"crossref","unstructured":"Rothman RB, Vu N, Partilla JS, Roth BL, Hufeisen SJ, Compton-Toth BA, Birkes J, Young R, and Glennon RA (2003) (+)-Fenfluramine and its major metabolite, (+)-norfenfluramine, are potent substrates for norepinephrine transporters. J Pharmacol Exp Ther 305: 1191-1199.","DOI":"10.1124\/jpet.103.049684"},{"key":"10.1124\/jpet.103.060806_bib24","doi-asserted-by":"crossref","unstructured":"Ruijtenbeek K, le Noble FA, Janssen GM, Kessels CG, Fazzi GE, Blanco CE, and De Mey JG (2000) Chronic hypoxia stimulates periarterial sympathetic nerve development in chicken embryo. Circulation 102: 2892-2897.","DOI":"10.1161\/01.CIR.102.23.2892"},{"key":"10.1124\/jpet.103.060806_bib25","doi-asserted-by":"crossref","unstructured":"Stamler R, Stamler J, Riedlinger WF, Algera G, and Roberts RH (1978) Weight and blood pressure. Findings in hypertension screening of 1 million Americans. J Am Med Assoc 240: 1607-1610.","DOI":"10.1001\/jama.240.15.1607"},{"key":"10.1124\/jpet.103.060806_bib26","doi-asserted-by":"crossref","unstructured":"Watts SW (1998) The development of enhanced arterial serotonergic hyperresponsiveness in mineralocorticoid hypertension. J Hypertens 16: 811-822.","DOI":"10.1097\/00004872-199816060-00012"},{"key":"10.1124\/jpet.103.060806_bib27","doi-asserted-by":"crossref","unstructured":"Watts SW (2002) Serotonin-induced contraction in mesenteric resistance arteries: signaling and changes in deoxycorticosterone acetate-salt hypertension. Hypertension 39: 825-829.","DOI":"10.1161\/hy0302.104668"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524313473?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524313473?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.103.060806","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T20:52:49Z","timestamp":1739998369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524313473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,5]]}},"alternative-id":["S0022356524313473"],"URL":"https:\/\/doi.org\/10.1124\/jpet.103.060806","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2004,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Fenfluramine Metabolite (+)-Norfenfluramine Is Vasoactive","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.103.060806","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2004 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}